Search company, investor...


Founded Year



Series A - II | Alive

Total Raised


Last Raised

$5.53M | 13 yrs ago

About Lumavita

Lumavita AG is a biopharmaceutical company focusing on novel anti-infectives for women's health. The Company's product portfolio includes FemiFect (pentamycin) a polyene macrolide with a unique spectrum of coverage for the treatment of vaginitis, and LMV-601, a first-in-class PC- PLC inhibitor for the potential treatment of infection of the cervix caused by Human Papilloma Virus. A dose-optimized formulation of FemiFect is in Ph IIb clinical development, and LMV-601 is in late-stage pre-clinical development. Lumavita AG is headquartered in Basle, Switzerland.

Headquarters Location

Engelgasse 77

Basel, 04052,


(+4) 161-225-4102

Missing: Lumavita's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Lumavita's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Lumavita

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Lumavita is included in 2 Expert Collections, including Women's Health & Wellness.


Women's Health & Wellness

1,482 items

Startups focused on providing products and services catering to women's health and wellbeing.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Lumavita Patents

Lumavita has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Autoimmune diseases, Dosage forms, Pharmaceutical industry, Animal virology, Amines


Application Date


Grant Date



Related Topics

Autoimmune diseases, Dosage forms, Pharmaceutical industry, Animal virology, Amines



Latest Lumavita News

Atlas Venture’s Ankit Mahadevia Promoted to Principal

Mar 3, 2011

Atlas Venture’s Ankit Mahadevia Promoted to Principal March 3, 2011 By PEHub Administrator Ankit Mahadevia, who joined the Cambridge, Mass.-based venture firm Atlas Venture in 2008, has been promoted to principal, according to the firm. Mahadevia, who focuses on biotech and medtech for Atlas, currently sits on the boards of Lumavita, based in Basel, Switzerland, and Fibrex Medical, headquartered in Cambridge. Lumativa is developing drugs to combat infections, including the Herpes Simplex Virus and Human Papillomavirus infections of the cervix. Fibrex is a biopharmaceutical company focusing on cardiovascular and inflammatory diseases. Previously, Mahadevia worked on product and business development with the founding team at Arcion Therapeutics, a specialty pharmaceutical company developing topical applications in neuropathic pain. Before Arcion Therapeutics, he held positions in Business Development at Genentech, and at Vanda Pharmaceuticals, a specialty pharmaceutical company focused on targeted therapies in psychiatry. He also served clients in the health services sector at McKinsey and Company. Mahadevia completed his MD at Johns Hopkins University School of Medicine, and his MBA at the Wharton School at the University of Pennsylvania. As an undergrad, he studied economics and biology at Northwestern University. © 2015 Buyouts Insider / Argosy Group LLC

Lumavita Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Lumavita Rank

Lumavita Frequently Asked Questions (FAQ)

  • When was Lumavita founded?

    Lumavita was founded in 2008.

  • Where is Lumavita's headquarters?

    Lumavita's headquarters is located at Engelgasse 77, Basel.

  • What is Lumavita's latest funding round?

    Lumavita's latest funding round is Series A - II.

  • How much did Lumavita raise?

    Lumavita raised a total of $22.23M.

  • Who are the investors of Lumavita?

    Investors of Lumavita include HealthCap Venture Capital, Endeavour Vision, Atlas Venture, BB Biotech Ventures and BioMedPartners.

  • Who are Lumavita's competitors?

    Competitors of Lumavita include Curetis, Eiger BioPharmaceuticals, GlobeImmune, Somaxon Pharmaceuticals, Nitec Pharma and 11 more.

Compare Lumavita to Competitors


StemPath is a development stage company focusing on the molecular pathways that regulate the regenerative capacity of stem cells in skeletal and cardiac muscles. The company is focusing to develop drugs that target signal transduction pathways, in particular for muscle wasting and Duchenne Muscular Dystrophy.


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

St Charles Pharmaceuticals

St Charles Pharmaceuticals, Inc. is a CNS drug development company exploiting approaches to therapeutic intervention by targeting the crossover of signaling pathways for pain and neuro-inflammation. The company's lead clinical candidate, SCP-123 (IND Enabling), is efficacious and safe in non-clinical studies, and is one of a series of safer and more potent non-opiod analgesics discovered by the company's founder, Dr. Nicolas Bazan. SCP's focus is translating early-stage compounds into clinical candidates. SCP is currently funded by SBIR grants, and is seeking to raise its first round of venture financing.


Apath is a pharmaceutical discovery and development company with a focus on the hepatitis C virus ("HCV") and other human viral pathogens. Apath was founded by Charles M. Rice, Ph.D., currently Professor of Molecular Microbiology, Rockefeller University and formerly of the Washington University (St. Louis) School of Medicine. Apath is engaged in the commercial application of virology and viral genetics to discover and develop a broad range of diagnostic and therapeutic products for viral infections, and for applications using viruses as vectors. Apath's primary focus is on RNA viruses. RNA viruses account for the majority of viruses which are human pathogens. In addition to HCV, they include several medically important viruses such as influenza, respiratory syncytial virus ("RSV"), and hemorrhagic fever viruses (e.g., Ebola).

Nano-Mite Technologies

Nano-Mite Technologies is engaged in R&D to control obesity using nanotechnology that alters the body's metabolic rate and increase the cell's ability to convert sugar to energy. Per the company, Nano-Mite's technnology could lead to futures in the treatment of traumatic central nervous system damage and neurodegenerative disorders.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.